iCMLf Conversations: Management of Advanced Phases of CML

Описание: Professor Mhairi Copland
Professor of Translational Haematology
University of Glasgow, UK

00:00 Welcome & Introduction
01:21 Disclosures
01:25 Outline
02:15 Progression to Blast Phase CML
03:22 Blast-Phase CML: Rare Disease, Poor Prognosis
04:22 Baseline Assessment & Monitoring Response to Therapy in BP-CML
05:46 Outcomes for Single Agent Imatinib in Historical Studies of TKI-Naive Patients
06:44 Outcomes for Single Agent 2G & 3G TKI's in BP
08:19 Is there an advantage to using Ponatinib?
09:06 Outcomes for Clinical Trials/Case Series of Combination Therapies in Myeloid BP?
09:55 Outcomes for Clinical Trials/Case Series of Combination Therapies in Lymphoid BP?
11:10 Matchpoint Trial
19:32 Allogenic Stem Cell Transplant Outcomes
20:41 ELN Guideline Recommendations for Treatment of BP-CML
21:39 NCCN Guideline Recommendations for Treatment of BP-CML
22:19 BSH Guideline Recommendations for Treatment of BP-CML
23:08 Novel Investigational Approaches in Myeloid BP-CML
24:09 Decitabine, Venetoclax & Ponatinib Triplet in Advanced Ph+ Myeloid Leukemias
24:57 Novel Investigational Approaches in Lymphoid BP-CML
25:50 Summary - How we Treat CML in the UK
27:58 The European LeukemiaNet Blast Crisis Registry
28:53 Questions
29:08 If you wanted to Further improve outcomes in Myeloid BC above what you have achieved with PON-FLAG-IDA, what would you like to study? What looks most promising?
30:20 When do you do maintenance after transplant, and for how long?
32:05 Is there a role for Asciminib in combination for BP-CML patients?
32:40 Have you seen relapse post-allograft after you have ceased the TKI?
34:38 What would be your preferred TKI for a patient with de novo blast crisis?
35:36 Do you have an upper age limit for giving FLAG-IDA?